Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS +5.84%37 3-Year FCF Growth Rate is 35.40% as of Dec. 2025, which is at its 10-year median of 35.40. GuruFocus rates XSWX:XLS with a GF Score™ of 37/100 and a GF Value™ of CHF7.07 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,111 Biotechnology companies, Xlife Sciences AG ranks better than 71.47% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 35.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Xlife Sciences AG was 59.60% per year. The lowest was -77.80% per year. And the median was 35.40% per year.
Xlife Sciences AG (XSWX:XLS) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Xlife Sciences AG 3-Year FCF Growth Rate Related Terms
XSWX:XLS vs VRTX, REGN, RVMD: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Xlife Sciences AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's 3-Year FCF Growth Rate falls into.
Xlife Sciences AG 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 35.40% mean?
Xlife Sciences AG (XSWX:XLS) has a 3-Year FCF Growth Rate of 35.40% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Xlife Sciences AG and its competitors. This is near median its historical median of 35.40. According to the industry distribution chart, Xlife Sciences AG ranks #317 out of 1111 companies in the Biotechnology industry, placing it in the top 28.5%.
Is Xlife Sciences AG's 3-Year FCF Growth Rate too high?
Xlife Sciences AG's current 3-Year FCF Growth Rate of 35.40% is near median its 10-year median of 35.40. The Biotechnology industry median 3-Year FCF Growth Rate is 19.20. Xlife Sciences AG's value of 35.40% is 84.4% above this industry median. Based on the distribution chart, Xlife Sciences AG ranks #317 out of 1111 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #317 out of 1111 companies for 3-Year FCF Growth Rate. This puts Xlife Sciences AG in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 19.20. Xlife Sciences AG's value of 35.40% is 84.4% above this benchmark. While the company's 10-year median is 35.40 vs. the industry median of 19.20, Xlife Sciences AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.20, based on 1,111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current 3-Year FCF Growth Rate of 35.40% is 84.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Xlife Sciences AG and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current 3-Year FCF Growth Rate is 35.40%, which is near median its own 10-year median of 35.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.07, compared to a current price of CHF16.30 — trading 130.6% above its estimated fair value. The current 3-Year FCF Growth Rate is 35.40%, which is near median its 10-year median of 35.40 and 84.4% above the Biotechnology industry median of 19.20. Xlife Sciences AG's overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current 3-Year FCF Growth Rate is 35.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF16.30 is trading 130.6% above its estimated GF Value™ of CHF7.07.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
3-Year FCF Growth Rate: 35.40% (near median its 10-year median of 35.40)
GF Value™: CHF7.07 vs. price of CHF16.30 (130.6% above fair value)
Industry Position: 84.4% above the Biotechnology median (#317 of 1111)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
37GF Score
Get the complete analysis for XSWX:XLS
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
